Method for analyzing primary biliary cirrhosis metabolite based on H1NMR technology

Abstract

The invention provides a method for analyzing primary biliary cirrhosis metabolites based on H1NMR technology, belongs to the field of biotechnology, and relates to primary biliary cirrhosis. The invention mainly comprises the following flow: step 1, sample collection and preparation, liver function testing; step 2, extraction, alignment, and normalization of original data; step 3, primary component analysis (PCA); step 4, orthogonal partial least squares-discriminant analysis (OPLS-DA); step 5, searching of metabolites causing intergroup differences; steo 6, statistical test. The advantages of the invention are that: the analysis method provided by the invention provides a new approach and method for the analysis research of primary biliary cirrhosis metabolites; the method has reasonable and feasible design, provides new landmarks for the research of the diagnosis and treatment of PCB, and also provides new thoughts for the research of the pathogenesis.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to primary biliary cirrhosis. Specifically provides a H-based 1 A method for the analysis of metabolites in primary biliary cirrhosis by NMR technique. Background technique [0002] Primary biliary cirrhosis (Primary Biliary Cirrhosis, PBC) is a type of chronic cholestatic disease mediated by autoimmune mechanisms and characterized by progressive, non-suppurative inflammation of small intrahepatic bile ducts. A recent survey conducted in the North American population shows that the annual incidence of PBC in the general population is 30.3 / 1,000,000, of which the annual incidences of males and females are 10.4 / 1,000,000 and 48.4 / 1,000,000, respectively. The prevalence is increasing year by year. The pathogenesis of PBC is that the combination of environmental and genetic factors leads to an autoimmune response against the liver, in which the most important antigen is the E2 subunit of th...

AI Technical Summary

Problems solved by technology

Although ursodeoxycholic acid (UDCA) can delay the progression of the disease to a certain extent, and liver transplantation can also save the lives of some advanced PBC patients, but the survey shows that the five-year survival rate of PBC is only about 80% since the establishment of the diagnosis. Lower survival than healthy controls

In the past few decades, although people's efforts to explore the pathogenesis of PBC have never stopped, there are still many unsolved mysteries about the specific molecular mechanism of PBC pathogenesis

Images